Project 5: Novel immunotherapeutic approaches for ovarian cancer

Specific Aims

• To assess fusions of ovarian carcinoma cells with immature and mature autologous DC by evaluating cytokine production (IL-12, IL-10) and potency of the fusions in generating tumor specific immunity in vitro
• To conduct a Phase I/II trial of the ovarian carcinoma-DC fusion vaccine generated with mature DC and administered with rhIL-12
• To assess the induction of immunity against ovarian cancer cells and MUC1 in patients treated with the fusion cell vaccine alone and with rhIL-12
• To perform a Phase II trial that will define the immunologic efficacy of the fusion cell vaccine and the rV-MUC1+rV-TRICOM vaccine in the treatment of patients with advanced ovarian cancer who have achieved a complete remission following primary chemotherapy

Publications

Vasir, Baldev, Wu Zekui, Crawford Keith, Rosenblatt J, Lenahan C, Bissonnette A, Kufe D, Avigan D. Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T cells While Concomitant Exposure to IL-12, CpG ODN, and anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells. J Immunol 2008;181(1):pg:808-821 PMCID 18566447

Comments:  In Project 5, the foundation has been laid for customized individual immune therapy for ovarian cancer in remission.  Fusing the patients’ own tumor cells with immune cells and using immune “adjuvants” hold promise for long term control of ovarian cancer that might otherwise develop chemotherapy resistance and relapse.

• 
• 
• 
  • Breast
  • Gastrointestinal Cancers
  • Kidney
  • Lung
  • Myeloma
  • Ovarian
    • Projects
    • Cores
    • Investigators
    • Awards
    • Calendar
  • Prostate
  • Skin
• 
• 
• 
•